1
|
Mills JL Sr: Buerger's disease in the 21st
century: Diagnosis, clinical features, and therapy. Semin Vasc
Surg. 16:179–189. 2003. View Article : Google Scholar : PubMed/NCBI
|
2
|
Kocak B and Ustun ED: Vasa nervorum as the
source of corkscrew collaterals in thromboangiitis obliterans
(Buerger's Disease). Eur J Vasc Endovasc Surg. 52:5082016.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Klein-Weigel PF and Richter JG:
Thromboangiitis obliterans (Buerger's disease). Vasa. 43:337–346.
2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Rivera-Chavarría IJ and Brenes-Gutiérrez
JD: Thromboangiitis obliterans (Buerger's disease). Ann Med Surg
(Lond). 7:79–82. 2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Highlander P, Southerland CC, VonHerbulis
E and Gonzalez A: Buerger disease (thromboangiitis obliterans): A
clinical diagnosis. Adv Skin Wound Care. 24:15–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Szuba A and Cooke JP: Thromboangiitis
obliterans. An update on Buerger's disease. West J Med.
168:255–260. 1998.PubMed/NCBI
|
7
|
Rimar D, Rozenbaum M, Slobodin G, Boulman
N, KaLy L and Rosner I: Thromboangiitis obliterans overlapping with
atherosclerotic occlusive arterial disease: Small merenteric artery
involvement by thromboangiitis obliterans. Harefuah. 155:41–44,
67,66. 2016.(In Hebrew). PubMed/NCBI
|
8
|
Abyshov NS, Abdullayev AG, Zakirdzhaev ED,
Guliyev RA, Akhmedov MB, Tagizade GT, Zeynalova GM and Mamedova LD:
The results of combined surgical treatment of thromboangiitis
obliterans and critical lower limb ischemia using prolonged
epidural analgesia and autohemotherapy with ozone. Khirurgiia
(Mosk). 9:45–50. 2016.(In Russian).
|
9
|
Aszalos C, Dongó E, Farkas Z, Kollár A,
Magyar P, Várallyay G, Bereczki D and Vastagh I: Cerebral
manifestations of thromboangiitis obliterans. Case report. Orv
Hetil. 157:1207–1211. 2016.(In Hungarian). View Article : Google Scholar
|
10
|
Kawarada O, Sakamoto S, Harada K, Ishihara
M, Yasuda S and Ogawa H: Endovascular recanalization of failed
distal bypass in Buerger's disease. Cardiovasc Interv Ther.
29:266–269. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Zeng R, Ye W, Li YJ, Shao J, Zheng YH and
Liu CW: Revascularization for lower limbs thromboangiitis
obliterans-early and mid-term outcome report. Zhonghua Wai Ke Za
Zhi. 51:719–722. 2013.(In Chinese). PubMed/NCBI
|
12
|
Shionoya S, Ban I, Nakata Y, Matsubara J,
Hirai M and Kawai S: Surgical treatment of Buerger's disease. J
Cardiovasc Surg (Torino). 21:77–84. 1980.PubMed/NCBI
|
13
|
Piazza G and Creager MA: Thromboangiitis
obliterans. Circulation. 121:1858–1861. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Owlia MB and Mehrpoor G: Thromboangiitis
obliterans with cryoglobulinemia. J Coll Physicians Surg Pak.
24:863–864. 2014.PubMed/NCBI
|
15
|
Modaghegh MH, Kazemzadeh GH, Ravari H,
Johari HG and Barzanuni A: Buerger's disease in the northeast of
Iran: Epidemiology and clinical features. Vascular. 23:519–524.
2015. View Article : Google Scholar : PubMed/NCBI
|
16
|
Sapkota P, Budhathoky P and Mathew S:
Smoking and Thromboangitis Obliterans - Are they related? JNMA J
Nepal Med Assoc. 52:802–805. 2014.PubMed/NCBI
|
17
|
Johnson JA and Enzenauer RJ: Inflammatory
arthritis associated with thromboangiitis obliterans. J Clin
Rheumatol. 9:37–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
18
|
Puéchal X and Fiessinger JN:
Thromboangiitis obliterans or Buerger's disease: Challenges for the
rheumatologist. Rheumatology (Oxford). 46:192–199. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Azizi M, Boutouyrie P, Bura-Rivière A,
Peyrard S, Laurent S and Fiessinger JN: Thromboangiitis obliterans
and endothelial function. Eur J Clin Invest. 40:518–526. 2010.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Hartge MM, Kintscher U and Unger T:
Endothelial dysfunction and its role in diabetic vascular disease.
Endocrinol Metab Clin North Am. 35:551–560. 2006. View Article : Google Scholar : PubMed/NCBI
|
21
|
Slavov ES, Stanilova SA, Petkov DP and
Dobreva ZG: Cytokine production in thromboangiitis obliterans
patients: New evidence for an immune-mediated inflammatory
disorder. Clin Exp Rheumatol. 23:219–226. 2005.PubMed/NCBI
|
22
|
Halacheva K, Gulubova MV, Manolova I and
Petkov D: Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on
the endothelium of femoral and iliac arteries in thromboangiitis
obliterans. Acta Histochem. 104:177–184. 2002. View Article : Google Scholar : PubMed/NCBI
|
23
|
Huang WY, Wang J, Liu YM, Zheng QS and Li
CY: Inhibitory effect of Malvidin on TNF-α-induced inflammatory
response in endothelial cells. Eur J Pharmacol. 723:67–72. 2014.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Dellalibera-Joviliano R, Joviliano EE,
Silva JS and Evora PR: Activation of cytokines corroborate with
development of inflammation and autoimmunity in thromboangiitis
obliterans patients. Clin Exp Immunol. 170:28–35. 2012. View Article : Google Scholar : PubMed/NCBI
|